TCGA-63-A5MN-01A-22R-A27Q-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 78
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_GAMMA_RESPONSE+0.590
- ALLOGRAFT_REJECTION+0.580
- IL6_JAK_STAT3_SIGNALING+0.560
- INTERFERON_ALPHA_RESPONSE+0.540
- INFLAMMATORY_RESPONSE+0.500
- COMPLEMENT+0.480
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.480
- TNFA_SIGNALING_VIA_NFKB+0.450
- TGF_BETA_SIGNALING+0.440
- HYPOXIA+0.380
Top 10 suppressed
- MYC_TARGETS_V2-0.470
- E2F_TARGETS-0.430
- OXIDATIVE_PHOSPHORYLATION-0.390
- G2M_CHECKPOINT-0.320
- MYC_TARGETS_V1-0.290
- FATTY_ACID_METABOLISM-0.270
- KRAS_SIGNALING_DN-0.260
- PANCREAS_BETA_CELLS-0.240
- SPERMATOGENESIS-0.240
- DNA_REPAIR-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-69-7978-01A-11R-2187-07 | — | cohortA1 | 0.944 |
| 2 | TCGA-A8-A096-01A-11R-A00Z-07 | — | B | 0.929 |
| 3 | MDT-AP-0390 | Med | Medulloblastoma | 0.920 |
| 4 | TCGA-FD-A3B8-01A-31R-A20F-07 | — | — | 0.916 |
| 5 | BS_49VCQD19 | Neurofibroma | — | 0.906 |
| 6 | c7a22797-676e-4f10-a51d-e3ee91a29a21 | — | — | 0.904 |
| 7 | SRR23303739 | — | — | 0.901 |
| 8 | SRR6013597 | — | cohortA1 | 0.900 |
| 9 | b02dc7a2-3615-4b6c-a3dd-a866d8561d9d | — | — | 0.899 |
| 10 | TCGA-FD-A3SP-01A-31R-A22U-07 | — | — | 0.896 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_GAMMA_RESPONSE | 0.590 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.580 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.560 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.540 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.500 | Idelalisib | — uncovered |
| COMPLEMENT | 0.480 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.480 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.450 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.440 | Inavolisib | — uncovered |
| HYPOXIA | 0.380 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.370 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.370 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.370 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.360 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.350 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.290 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.280 | Inavolisib | — uncovered |
| COAGULATION | 0.270 | Binimetinib | — uncovered |